In a man with aggressive metastatic prostate cancer (expected survival ≤5 years) undergoing androgen‑deprivation therapy and chemotherapy, is sexual activity possible and what options exist to preserve or restore erectile function?

Sexual Activity Remains Possible for Many Men with Aggressive Metastatic Prostate Cancer on ADT

Sexual life is not necessarily over—approximately 10-20% of men maintain sexual interest and some degree of sexual activity during androgen deprivation therapy, and multiple evidence-based interventions can help preserve or restore sexual function even in this setting 1, 2, 3.

The Reality: Sexual Function Changes But Doesn't Always End

While ADT profoundly impacts sexual function, the assumption that sex life is completely over is incorrect:

• At baseline before ADT: About 50% of men with metastatic prostate cancer are sexually active 3
• During ADT: Approximately 8-10% remain sexually active, meaning roughly 1 in 5 men who were sexually active before ADT maintain some sexual activity during treatment 3
• Sexual interest persists: In one study, 29 of 76 men (38%) maintained interest in sexual activity despite severe erectile dysfunction, with emotional connection to their partner being the primary motivator 4
• Quality of life can actually improve: Men with newly diagnosed metastatic disease experience improved overall quality of life and emotional function after starting ADT, despite worsening hormonal symptoms 2

Evidence-Based Interventions to Preserve Sexual Function

First-Line: PDE5 Inhibitors Combined with Counseling

Start phosphodiesterase type 5 inhibitors (sildenafil, tadalafil, vardenafil) early and combine with psychosocial counseling for both the patient and partner 1. This combination approach is superior to either intervention alone.

Key implementation details:

• Begin with conservative dosing and titrate to maximum dose if needed
• An adequate trial requires at least 5 separate attempts at maximum dose before declaring failure 5
• If first PDE5i fails, try a different one before moving to second-line options 5
• Contraindication: Absolutely no concurrent nitrate use in any form 1
• Common side effects: headaches, flushing, dizziness, nasal congestion, dyspepsia 1

Penile Rehabilitation: Prevent Tissue Atrophy

Use vacuum erectile devices (VEDs) daily to prevent penile length loss and tissue atrophy—start as early as possible after beginning ADT 1. Early PDE5i treatment may also help preserve erectile tissue 1.

The rationale: ADT causes irreversible damage to erectile tissue within 3-4 months, and about 50% of men never recover erectile function even if ADT is discontinued 6. Proactive rehabilitation is critical.

Reframe Sexual Intimacy Beyond Penetration

Offer couples counseling focused on redefining sexual intimacy and integrating non-penetrative activities 1. This is particularly important because:

• Men on ADT who maintain sexual interest are primarily motivated by emotional connection with their partner (not physical pleasure or orgasm) 4
• Regular sexual stimulation of any kind—including masturbation—likely benefits sexual response 1
• Traditional models of sexuality (Masters & Johnson, Kaplan) don't fit the experience of men on ADT; intimacy and emotional connection become paramount 4

Second-Line Options When PDE5i Fails

After adequate trials of two different PDE5 inhibitors, refer to urology for 5:

• Intraurethral alprostadil suppositories
• Intracavernous vasoactive drug injection therapy
• Vacuum constriction devices (if not already using for rehabilitation)

Third-Line: Penile Prosthesis

For men with complete erectile failure who desire penetrative intercourse, penile prosthesis implantation is a definitive option 5. This is particularly relevant when ADT causes venous leak syndrome from tissue atrophy.

Critical Counseling Points

Set Realistic Expectations

• PDE5 inhibitors may take considerable time to work and won't work for everyone, especially with pre-existing comorbidities 1
• Response to erectogenic medications is significantly impaired during ADT 7
• If ADT is intermittent, testosterone recovery requires 9-12 months off treatment, and 50% still have permanent erectile dysfunction 6

Address the Partner

Always offer—not require—partner involvement in counseling and treatment planning 1. Partner engagement facilitates adaptation and emphasizes flexible coping strategies 8.

Manage Hormonal Side Effects

For vasomotor symptoms (hot flashes) that interfere with quality of life, offer 1:

• Venlafaxine
• Medroxyprogesterone acetate
• Cyproterone acetate
• Gabapentin
• Acupuncture or integrative techniques (slow breathing, hypnosis)

Monitor and Support Body Image

Discuss and normalize weight changes, gynecomastia, hair loss, and other body image concerns 1. These significantly impact sexual confidence.

The Adaptation Framework

Men who successfully adapt sexually after ADT fall into distinct patterns 8:

Couples-focused adaptations (better outcomes):

• Relationship renegotiation: Redefining intimacy and priorities together
• Sexual renegotiation: Finding new ways to be sexual as a couple

Individual-focused adaptations:

• Acceptance/resignation: Abandoning partnered sexual activity
• Masturbation/erection focus: Emphasis on restoring penetrative function

Critical finding: Men who engage in ANY adaptation style fare significantly better than those who don't adapt. Those who don't adapt show higher depression rates, lower relationship adjustment, and greater dissatisfaction 8.

Common Pitfalls to Avoid

1. Assuming all men lose interest in sex: About 40% maintain interest despite severe dysfunction 4
2. Waiting to address sexuality: Start penile rehabilitation and counseling immediately when beginning ADT 1
3. Giving up after one PDE5i fails: Try a second agent before declaring failure 5
4. Focusing only on erections: Emotional connection and intimacy are often more important motivators than physical function 4
5. Excluding the partner: Partner involvement significantly improves adaptation outcomes 8

Bottom Line Algorithm

1. At ADT initiation: Start daily VED use + discuss sexual expectations with patient and partner
2. Simultaneously: Begin PDE5i (if no contraindications) + couples counseling focused on intimacy redefinition
3. If PDE5i fails: Try second PDE5i agent (minimum 5 attempts at max dose each)
4. If both fail: Refer to urology for intraurethral/intracavernous therapy or prosthesis evaluation
5. Throughout: Encourage any form of sexual stimulation, address body image concerns, treat vasomotor symptoms

The goal is not necessarily to restore pre-cancer sexual function, but to maximize sexual satisfaction and intimacy within the constraints of treatment 1.